In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to ...
Pfizer has agreed to settle more than 10,000 lawsuits which alleged that the company failed to warn patients about possible cancer risks caused by the anti-heartburn medication Zantac. The ...
Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its ...
Pfizer has reached a major settlement in a legal battle concerning its recalled heartburn medication, Zantac. According to a Bloomberg report, Pfizer has agreed to settle over 10,000 lawsuits that ...
Following the lead of French pharmaceutical giant Sanofi, Pfizer has agreed to settle more than 10,000 personal-injury claims from users of heartburn drug Zantac, resolving litigation in several U ...
, opens new tab has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people ...
Despite this significant resolution, the settlement does not completely absolve Pfizer from its Zantac-related legal challenges. Concerns surrounding potential liabilities stemming from Zantac ...
Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with ...
Pfizer has agreed to settle more than 10,000 lawsuits alleging it it of hiding the cancer risks of its heartburn drug Zantac. The financial details have not been revealed but pharma rival Sanofi ...
Estimación del precio real de una acción basada en modelos de valoración como el flujo de caja descontado, los múltiplos de valoración por pares y los modelos de descuento de dividendos.